Relmada Therapeutics, Inc. (RLMD) Stock Price & Analysis
Relmada Therapeutics, Inc. (RLMD) closed at USD 3.2 on Thursday, October 15, 2026, down 1.23% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 3.24; the Oct 15, 2026 session ranged USD 3.19–3.35 on volume of 908,691 shares. Market capitalization is $341.34M, with a 52-week range of USD 1.8–8 (NCM). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/RLMD.md
Key facts (RLMD)
- Analysts: Buy (mean 1.75 on a 1–5 scale) (4 analysts), mean target USD 10.75 (range 9–12).
- Total return with dividends: 1Y +59.2% vs S&P 500 +18.1%; 5Y -86.5% vs S&P 500 +85.1%.
- Next earnings: 2026-11-12, EPS estimate USD -0.15, revenue estimate $0K.
Analysts (RLMD)
Consensus Buy (mean 1.75 on a 1–5 scale), 4 analysts; mean target USD 10.75 (low 9, high 12).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-18 | HC Wainwright & Co. | Initiated | Buy | $12 |
Total return (dividends reinvested) (RLMD)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +59.2% | -86.5% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +59.5% | -32.9% |
| Volatility (annualized) | 89.1% | 148.9% |
| Max drawdown | -59.7% (May 2026→Oct 2026) | -99.3% (Sep 2022→Feb 2025) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 3.2 |
|---|---|
| Change | ▼ 1.23% (down) |
| Previous Close | USD 3.24 |
| Open | USD 3.27 |
| Day Range | USD 3.19 – 3.35 |
| 52-Week Range | USD 1.8 – 8 |
| Volume | 908,691 shares |
| Market Cap | $341.34M |
| Exchange | NCM |
Technical Analysis (RLMD)
Nexqual's technical model rates RLMD "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 32.8 (neutral) |
| vs SMA50 | Below (USD 4.17) |
| MACD | -0.29 (negative) |
Analyst Ratings (RLMD)
Wall Street analysts rate RLMD "Buy" based on 4 analysts, with a mean price target of USD 10.75 (range USD 9–12), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 4 |
| Mean Target | USD 10.75 |
| High Target | USD 12 |
| Low Target | USD 9 |
| Buy / Hold / Sell | 4 / 0 / 0 |
Earnings (RLMD)
| Next Earnings Date | 2026-11-12 |
|---|---|
| Revenue Estimate | $0 |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.11 vs est -0.2 ▲ beat |
| 2025-12-31 | USD -0.29 vs est -0.14 ▼ miss |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (RLMD)
| Gross Margin | +0.00% |
|---|---|
| Operating Margin | +0.00% |
| Profit Margin | +0.00% |
| ROE | -55.66% |
| Current Ratio | 29.52 |
| Total Cash | $217.73M |
| Total Debt | $0 |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (RLMD)
Nexqual rates Relmada Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $218M cash, no debt |
| Cash Flow | Weak — Operating cash flow -$46M (TTM) |
| Efficiency | Critical — ROE -56%, ROA -32.4% |
Ownership (RLMD)
| Insider Ownership | +3.23% |
|---|---|
| Institutional Ownership | +94.68% |
| Shares Outstanding | 106.67M |
| Float | 82.64M |
| Short % of Float | +13.36% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (RLMD)
Relmada Therapeutics, Inc. is led by Sergio Traversa M.B.A., Pharm.D. (age 65), CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO & Director | Sergio Traversa M.B.A., Pharm.D. (age 65) |
|---|---|
| Chief Financial Officer | Maged S. Shenouda M.B.A., R.Ph. (age 61) |
| COO & Director | Paul E. Kelly (age 68) |
Major Backers & Investors (RLMD)
Notable institutional backers of Relmada Therapeutics, Inc. include Adage Capital Partners GP L.L.C., Jones Hill Capital LP, Orbimed Advisors LLC., according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Adage Capital Partners GP L.L.C. | 48.14% |
| Jones Hill Capital LP | 36.94% |
| Orbimed Advisors LLC. | 36.7% |
| MUTUAL FUND SERIES TRUST-Eventide Healthcare & Life Sciences Fund | 18.78% |
| Fidelity | 15.11% |
| Franklin Strategic Series-Franklin Biotechnology Discovery Fund | 7.97% |
| AdvisorShares Trust-AdvisorShares Psychedelics ETF | 6.78% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| State Street | 38.64% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 87.97 | ▲ 1.57% |
| BLTE | Belite Bio, Inc | USD 152.62 | ▲ 0.49% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.72 | ▲ 1.52% |
| PRAX | Praxis Precision Medicines, Inc | USD 248.24 | ▲ 2.01% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 44.12 | ▲ 4.11% |
| SYRE | Spyre Therapeutics, Inc. | USD 80.1 | ▼ 0.44% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt